Cargando…
Interleukin 2 therapy in cancer: identification of responders.
C-reactive protein (CRP) levels in serum were measured in fifteen patients with metastatic colorectal carcinoma, prior to and during treatment with a continuous intravenous infusion of rIL.2. Patients were subsequently classified as responders or non-responders to this therapy. Baseline serum CRP le...
Autores principales: | Broom, J., Heys, S. D., Whiting, P. H., Park, K. G., Strachan, A., Rothnie, I., Franks, C. R., Eremin, O. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1992
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1978053/ https://www.ncbi.nlm.nih.gov/pubmed/1457363 |
Ejemplares similares
-
In vivo cytokine production and recombinant interleukin 2 immunotherapy: an insight into the possible mechanisms underlying clinical responses.
por: Deehan, D. J., et al.
Publicado: (1994) -
Reply to the letter from Blay et al: Pretreatment serum CRP and response to interleukin 2
por: Heys, Steven D., et al.
Publicado: (1994) -
Macrophages produce and functionally respond to interleukin-34 in colon cancer
por: Franzè, Eleonora, et al.
Publicado: (2020) -
Cytotoxic T cells both produce and respond to interleukin 2
por: Andrus, L, et al.
Publicado: (1984) -
Dietary supplementation with L-arginine in patients with breast cancer (> 4 cm) receiving multimodality treatment: report of a feasibility study.
por: Brittenden, J., et al.
Publicado: (1994)